Trial Profile

Phase II trial of EMA 401 for the treatment of pain and hypersensitivity in patients with peripheral nerve injuries.

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 08 Jun 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Olodanrigan (Primary)
Indications Neuropathic pain
Focus Therapeutic Use
Sponsors Spinifex Pharmaceuticals

Most Recent Events

27 Feb 2014 Status changed from not yet recruiting to discontinued, as reported by Australian New Zealand Clinical Trials Registry.
24 Jul 2012 Planned initiation date changed from 1 Mar 2012 to 1 Feb 2013 as reported by Australian New Zealand Clinical Trials Registry.
06 Dec 2011 Planned patient number is 40 according Australian New Zealand Clinical Trials Registry record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com